Bisphosphonate-related Osteonecrosis of the Jaw: Specificities

Overview

Journal Oncol Rev

Specialty Oncology

Date 2015 May 21

PMID 25992241

Citations 17

Authors

Siri Paulo

Ana Margarida Abrantes

Mafalda Laranjo

Lina Carvalho

Armenio Serra

Maria Filomena Botelho

Manuel Marques Ferreira

Affiliations

Soon will be listed here.

Abstract

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication that has recently emerged in patients treated with intravenous bisphosphonates for malignant diseases. This complication usually presents after a minor local trauma during a dental treatment. Several etiopathogenic mechanisms of this pathological condition have been proposed, but no model can explain all morphological changes observed at the macroscopic and microscopic level. BRONJ is likely to be related to direct toxicity in the bone and soft tissue cells, due to nitrogen-containing bisphosphonates. This review elucidates the clinical indications and mechanism of action of bisphosphonates, reports some clinical diagnostic criteria for BRONJ, describe the histopathological criteria for BRONJ diagnosis, the potential triggering pathways and the available treatment strategies.

Citing Articles

The Role of Apical Periodontitis Disease in the Development of Bisphosphonate-Related Osteonecrosis of the Jaw: An Animal Study.

Marques-Ferreira M, Abrantes A, Paula A, Laranjo M, Pires A, Caramelo F Dent J (Basel). 2023; 11(7).

PMID: 37504234 PMC: 10377877. DOI: 10.3390/dj11070168.

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.

Robijns J, Nair R, Lodewijckx J, Arany P, Barasch A, Bjordal J Front Oncol. 2022; 12:927685.

PMID: 36110957 PMC: 9468822. DOI: 10.3389/fonc.2022.927685.

A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.

Bullock G, Miller C, McKechnie A, Hearnden V Front Oral Health. 2022; 2:822411.

PMID: 35224540 PMC: 8865370. DOI: 10.3389/froh.2021.822411.

Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw.

Blatt S, Kruger M, Kammerer P, Thiem D, Matheis P, Eisenbeiss A J Clin Med. 2022; 11(3).

PMID: 35160132 PMC: 8837070. DOI: 10.3390/jcm11030682.

Application of a collagen scaffold saturated with platelet-rich plasma in prevention of bisphosphonate-related osteonecrosis of the jaw in the rat animal model.

Razmara F, Bayat M, Shirian S, Shabankare G, Mohamadnia A, Mortazavi M Heliyon. 2021; 7(5):e06930.

PMID: 34007929 PMC: 8111602. DOI: 10.1016/j.heliyon.2021.e06930.

References

Walter C, Klein M, Pabst A, Al-Nawas B, Duschner H, Ziebart T . Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 2009; 14(1):35-41. DOI: 10.1007/s00784-009-0266-4. View

Freiberger J . Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):96-106. DOI: 10.1016/j.joms.2008.12.003. View

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

Lemound J, Eckardt A, Kokemuller H, von See C, Voss P, Tavassol F . Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. Clin Oral Investig. 2011; 16(4):1143-52. DOI: 10.1007/s00784-011-0596-x. View

Evian C, Rosenberg E, Coslet J, Corn H . The osteogenic activity of bone removed from healing extraction sockets in humans. J Periodontol. 1982; 53(2):81-5. DOI: 10.1902/jop.1982.53.2.81. View

Pabst A, Ziebart T, Koch F, Taylor K, Al-Nawas B, Walter C . The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clin Oral Investig. 2011; 16(1):87-93. DOI: 10.1007/s00784-010-0507-6. View

Papapoulos S . Bisphosphonates: how do they work?. Best Pract Res Clin Endocrinol Metab. 2008; 22(5):831-47. DOI: 10.1016/j.beem.2008.07.001. View

Polascik T . Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 2009; 3:27-40. PMC: 2769231. View

Chaveli-Lopez B . Oral toxicity produced by chemotherapy: A systematic review. J Clin Exp Dent. 2014; 6(1):e81-90. PMC: 3935911. DOI: 10.4317/jced.51337. View

10.

Cozin M, Pinker B, Solemani K, Zuniga J, Dadaian S, Cremers S . Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. J Oral Maxillofac Surg. 2011; 69(10):2564-78. PMC: 3179815. DOI: 10.1016/j.joms.2011.03.005. View

11.

Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis M . Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 112(2):195-202. DOI: 10.1016/j.tripleo.2011.02.037. View

12.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. DOI: 10.1016/j.joms.2009.01.009. View

13.

Sarin J, DeRossi S, Akintoye S . Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 2008; 14(3):277-85. DOI: 10.1111/j.1601-0825.2007.01381.x. View

14.

Ziebart T, Koch F, Klein M, Guth J, Adler J, Pabst A . Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. Oral Oncol. 2011; 47(3):195-201. DOI: 10.1016/j.oraloncology.2010.12.003. View

15.

Assaf A, Smeets R, Riecke B, Weise E, Grobe A, Blessmann M . Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013; 33(9):3917-24. View

16.

Cremers S, Papapoulos S . Pharmacology of bisphosphonates. Bone. 2011; 49(1):42-9. DOI: 10.1016/j.bone.2011.01.014. View

17.

Mozzati M, Arata V, Gallesio G . Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012; 48(9):817-21. DOI: 10.1016/j.oraloncology.2012.03.009. View

18.

Kuhl S, Walter C, Acham S, Pfeffer R, Lambrecht J . Bisphosphonate-related osteonecrosis of the jaws--a review. Oral Oncol. 2012; 48(10):938-947. DOI: 10.1016/j.oraloncology.2012.03.028. View

19.

Lesclous P, Abi Najm S, Carrel J, Baroukh B, Lombardi T, Willi J . Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?. Bone. 2009; 45(5):843-52. DOI: 10.1016/j.bone.2009.07.011. View

20.

Watts N, Marciani R . Osteonecrosis of the jaw. South Med J. 2008; 101(2):160-5. DOI: 10.1097/SMJ.0b013e31816127d9. View